NSE filing, NSE: DELHIVERY. Summary written from the filing by ALFA Finder's alert engine.
Delhivery Ltd: key numbers
- Share price
- ₹408.75
- Market cap
- ₹30,637 Cr
- Revenue (annual)
- ₹10,508 Cr
- Net profit (annual)
- ₹152.7 Cr
- P/E (TTM)
- 166.0×Sector 27.7×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 39.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Delhivery Ltd
All →Delhivery Capital Structure Change
Delhivery will infuse up to Rs.36 Crore into its wholly owned subsidiary DFDPL in tranches. The funds support the subsidiary's fintech distribution business for logistics participants.
- Value
- ₹36.00 Cr
- Execution
- In one or more tranches, as per DFDPL's business requirement, up to Rs.36 Crore.
Delhivery Investor Presentation: Key Takeaways
Q2FY27 revenue from services ₹3,066 Cr (+19.8% YoY), adj. EBITDA ₹123 Cr (4.0% margin), PAT ₹41 Cr vs prior-year loss of ₹51 Cr. Express parcel growth leads; cash ₹4,676 Cr.
Delhivery Results Update
Delhivery reported Q2FY27 revenue from services of ₹3,066 Cr, up 20% YoY, with EBITDA tripling to ₹205 Cr. Consolidated PAT stood at ₹41 Cr.
Delhivery Q2 FY27 Results: Turns Profitable, Net Profit ₹40.6 Cr
Delhivery Ltd reported revenue from operations of ₹3,066 Cr (+19.8% YoY) and net profit of ₹40.6 Cr for Q2 FY27.
- Key figure
- Net profit ₹40.6 Cr
Delhivery Legal & Regulatory
Delhivery's subsidiary Ecom Express received a UP GST order confirming a tax demand, interest and penalty. The penalty is Rs.0.18 Crore, and management expects no material impact.
- Value
- ₹0.18 Cr
Delhivery Legal & Regulatory
Ecom Express, Delhivery's subsidiary, received a UP GST order for FY 2022-23 confirming ₹3.30 Crore including interest and penalty. No material impact expected, per management.
- Value
- ₹3.30 Cr
Other regulatory approval announcements
All →Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Som Distilleries & Breweries Regulatory Approval
Som Distilleries received manufacturing licences for its Bhopal plant from the Madhya Pradesh Excise Department, plus product label and rate approvals. Manufacturing and sales are expected to resume soon.
AGI Infra Regulatory Approval
Agi Infra received RERA registration PBRERA-SAS80-PR1452-102026 from Punjab RERA for its Utopia by AGI group housing project in New Chandigarh. The registration is valid until 30 March 2031.
- Execution
- Valid up to March 30, 2031
360 One Wam Regulatory Approval
360 ONE Distribution Services' IFSC branch, a subsidiary of 360 ONE WAM, received an IFSCA Certificate of Registration to act as broker dealer, clearing member, depository participant, research entity and distributor. This is a regulatory licence authorising new activities in the IFSC.
Nesco Regulatory Approval
Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.
Grasim Industries Regulatory Approval
CCI approved subsidiary ABReN's acquisition of 100% of Solenergi Power from Shell Overseas. The approval clears a regulatory condition for the deal announced on 13 July 2026.